168 related articles for article (PubMed ID: 9543688)
1. Ay-4166 increases the sensitivity of insulin secretion to glucose in isolated perfused rat pancreas.
Morimoto S; Mokuda O; Sakamoto Y
Horm Metab Res; 1998 Feb; 30(2):77-9. PubMed ID: 9543688
[TBL] [Abstract][Full Text] [Related]
2. Effects of N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) on insulin and glucagon secretion in isolated perfused rat pancreas.
Hirose H; Maruyama H; Ito K; Seto Y; Kido K; Koyama K; Dan K; Saruta T; Kato R
Pharmacology; 1994 Apr; 48(4):205-10. PubMed ID: 8177906
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas.
Fujitani S; Ikenoue T; Akiyoshi M; Maki T; Yada T
Metabolism; 1996 Feb; 45(2):184-9. PubMed ID: 8596487
[TBL] [Abstract][Full Text] [Related]
4. Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide.
Hirose H; Maruyama H; Seto Y; Ito K; Fujita T; Dan K; Kanda N; Saruta T; Kato R
Pharmacology; 1995 Mar; 50(3):175-81. PubMed ID: 7746834
[TBL] [Abstract][Full Text] [Related]
5. Contrasting effects of nateglinide and rosiglitazone on insulin secretion and phospholipase C activation.
Zawalich WS; Tesz G; Zawalich KC
Metabolism; 2003 Nov; 52(11):1393-9. PubMed ID: 14624396
[TBL] [Abstract][Full Text] [Related]
6. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
Hu S; Wang S; Dunning BE
Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of the cationic and secretory responses to A-4166 in perifused pancreatic islets.
Jijakli H; Ulusoy S; Malaisse WJ
Fundam Clin Pharmacol; 1997; 11(4):300-4. PubMed ID: 9263759
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ
Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
[TBL] [Abstract][Full Text] [Related]
9. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
[TBL] [Abstract][Full Text] [Related]
10. Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound.
Furukawa N; Ohta T; Noguchi T; Yonemori F; Wakitani K
Eur J Pharmacol; 1999 Apr; 371(1):51-8. PubMed ID: 10355594
[TBL] [Abstract][Full Text] [Related]
11. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
Hu S
Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
[TBL] [Abstract][Full Text] [Related]
12. Insulin secretion from isolated rat islets induced by the novel hypoglycemic agent A-4166, a derivative of D-phenylalanine.
Tsukuda K; Sakurada M; Niki I; Oka Y; Kikuchi M
Horm Metab Res; 1998 Jan; 30(1):42-9. PubMed ID: 9503038
[TBL] [Abstract][Full Text] [Related]
13. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).
Ikenoue T; Akiyoshi M; Fujitani S; Okazaki K; Kondo N; Maki T
Br J Pharmacol; 1997 Jan; 120(1):137-45. PubMed ID: 9117089
[TBL] [Abstract][Full Text] [Related]
15. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
Shigeto M; Katsura M; Matsuda M; Ohkuma S; Kaku K
J Pharmacol Exp Ther; 2007 Jul; 322(1):1-7. PubMed ID: 17409272
[TBL] [Abstract][Full Text] [Related]
16. Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide.
McClenaghan NH; Flatt PR; Ball AJ
J Endocrinol; 2006 Sep; 190(3):889-96. PubMed ID: 17003289
[TBL] [Abstract][Full Text] [Related]
17. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.
Mori Y; Kitahara Y; Miura K; Tajima N
Endocrine; 2004 Feb; 23(1):39-43. PubMed ID: 15034195
[TBL] [Abstract][Full Text] [Related]
18. [Preclinical studies of AY4166 (A-4166)].
Kondo N
Nihon Rinsho; 1997 Nov; 55 Suppl():159-63. PubMed ID: 9434461
[No Abstract] [Full Text] [Related]
19. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of insulin and somatostatin release by two meglitinide analogs.
Leclercq-Meyer V; Ladrière L; Fuhlendorff J; Malaisse WJ
Endocrine; 1997 Dec; 7(3):311-7. PubMed ID: 9657067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
